菜单
CRO Services

Drug Development Expertise Empowering Research Services for Biologics

Antibody Discovery Services


Customized Antibody Discovery Platforms with Speed & Quality

Each drug discovery project demands a tailored approach. Backed by industry-leading expertise, we offer customized antibody discovery platforms for monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), multispecific antibodies (msAbs), immunocytokines, and other therapeutic modalities. With over 20 client programs currently in clinical development and two on the market, we deliver quality-assured solutions with industry-leading technologies to accelerate biology-driven lead identification.

 

Industry-leading antibody discovery platforms including hybridoma, phage display, yeast display and B cell screening.

Frequently Asked Questions for Antibody Discovery

Q: How do monoclonal and bispecific antibody discovery approaches differ?

A: Monoclonal antibody discovery focuses on developing highly specific antibodies against a single target. In contrast, bispecific antibody discovery engineers molecules that bind to two different targets simultaneously, enabling enhanced therapeutic effects. BsAb discovery is more than combining two parental antibodies. Their formats are keys for enhancing the potency and achieving the desired safety window.

Q: What factors influence the success rate of antibody candidate discovery?

A: Key factors include target product profile design, antigen selection, diversity of antibody libraries, platform choice (e.g., hybridoma vs. display vs. single B cells), and robust screening methods. For bispecific antibodies, valency, geometry, synapse distance, PK, and developability assessments like stability and aggregation risks, are critical to ensure the advancement of promising bsAb candidates to drug development stage.

Q: How does single B cell technology compare with phage/yeast display in antibody discovery?

A: Single B cell technology enables rapid isolation of natural antibodies directly from human or immunized animals. Phage/yeast display provides flexible engineering options, such as isolating hits tailored toward pH-sensitivity, cross-species reactivity and epitope specificity. Both are powerful platforms with selection depending on project goals.

Q: What are the key steps in therapeutic antibody discovery?

A: Discovery involves target selection, hit identification (via hybridoma, display platforms, or single B cell technologies), lead optimization, protein production, and functional validation. We recommend employing early-stage developability assessments in each step to ensure antibodies meeting safety, efficacy, and developability requirements.

Q: How is in silico analysis applied to antibody discovery?

A: In silico methods employ computational tools to predict antibody structure, immunogenicity, and developability risks. These approaches accelerate discovery by guiding molecular design and minimizing the need for costly experimental iterations.

Q: Why is protein engineering important in antibody discovery?

A: Protein engineering is an integral part of lead optimization, aimed at improving the biophysical and biochemical properties of a molecule. It can enhance half-life, reduce immunogenicity, improve thermal stability, binding affinity, developability, and manufacturability, and enable the creation of novel formats such as bispecific antibodies or antibody-drug conjugates. Common protein engineering techniques used in lead optimization include site-directed mutagenesis, 3D model-guided design, and in silico sequence optimization.

Q: What role does the Fc region play in antibody therapeutics?

A: The Fc region plays a crucial role in antibody function, contributing not only to structural stability but also to immune effector mechanisms such as ADCC, CDC, ADCP, and antibody recycling. Through Fc engineering, these properties can be fine-tuned to enhance efficacy, extend half-life, or reduce unwanted immune activation.

Your Project. Our Expertise.